目的 分析孟鲁司特钠片联合硫酸镁注射液对支气管哮喘患者肺功能的影响。方法 采用简单随机化分组方法将96例 支气管哮喘患者分为研究组与对照组各48例。对照组予以常规支气管哮喘治疗，研究组在前者基础上同时使用孟鲁 司特钠片与硫酸镁注射液。比较两组患者治疗前、治疗3个月后肺功能指标[第一秒用力呼气量(FEV1)占预计的值、 第一秒用力呼气量占用力肺活量比值(FEV1/FVC)、呼气峰值流速(PEF)]、症状缓解时间(喘息、咳嗽、胸闷)、心理 状态[临床症状自评量表(SCL-90)]评估的情况。结果 治疗3个月后，两组患者肺功能指标(FEV1、FEV1/FVC、PEF)水 平均较治疗前显著提高，且研究组提高程度高于同期对照组(P＜0.05)，症状缓解时间、SCL-90评分均较治疗前明 显减少，且研究组减少程度高于对照组(P＜0.05)。所有患者均未出现呼吸困难、血压下降等严重不良反应。结论 孟鲁司特钠片与硫酸镁注射液共同使用对支气管哮喘患者的治疗效果显著，于患者病情转归有利。

Objective To analyze the effects of montelukast sodium tablets combined with magnesium sulfate injection on pulmonary function in patients with bronchial asthma. Methods 96 patients with bronchial asthma were divided into study group and control group according to the simple randomized grouping method, with 48 cases in each group. Control group was given conventional bronchial asthma, and study group was given montelukast sodium tablets and magnesium sulfate injection on the basis of the former. Thepulmonary function indexes [ratio of forced expiratory volume in 1st second(FEV1) in predicted value, ratio of forced expiratory volume in 1st second in forced vital capacity(FEV1/FVC), peak expiratory flow(PEF)], symptom relief time(wheezing, cough, chest tightness) and psychological status [Clinical Symptom Checklist(SCL-90)] were compared between the two groups before treatment and after 3 months of treatment. Results After 3 months of treatment, thelevels of pulmonary function indexes (FEV1, FEV1/FVC, PEF) in the two groups were significantly higher than those before treatment, and the improvements in study group were higher than those in control group(P<0.05), and the symptom relief time and SCL-90 score were significantly lower than those before treatment, and the reductionsin study group were higher than those in control group(P<0.05). There were no serious adverse reactions such as dyspnea and blood pressure reduction. Conclusion Montelukast sodium tablets combined with magnesium sulfate injection has significant treatment effects on patients with bronchial asthma, and it is beneficial to disease outcomes of patients.